Literature DB >> 21431305

Role of microRNAs in cardiac remodeling and heart failure.

Veli K Topkara1, Douglas L Mann.   

Abstract

MicroRNAs (miRNAs) are endogenous, short (~22 nucleotide), evolutionarily conserved, non-coding RNAs that regulate gene expression at the post-transcriptional level. Recent evidence suggests that miRNAs are differentially expressed in the failing myocardium and play an important role in progression of heart failure by targeting genes that govern diverse functions in cardiac remodeling process including myocyte hypertrophy, excitation-contraction coupling, increased myocyte loss, and myocardial fibrosis. In addition to their role in adverse cardiac remodeling, miRNAs hold promise as biomarkers of disease progression in heart failure given their presence in circulation and enhanced stability. Further development of miR-based therapeutics may allow for modulation of cardiac and/or systemic levels of specific miRNAs in patients with heart failure . Here, we summarize current knowledge of miRNAs in relation to their role in regulating various aspects of the cardiac remodeling process and discuss their potential use as biomarkers and/or therapeutic targets in heart failure.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21431305     DOI: 10.1007/s10557-011-6289-5

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  56 in total

Review 1.  Diagnostic and prognostic value of circulating microRNAs in heart failure with preserved and reduced ejection fraction.

Authors:  Christian Schulte; Dirk Westermann; Stefan Blankenberg; Tanja Zeller
Journal:  World J Cardiol       Date:  2015-12-26

2.  NF-κB-mediated miR-30b regulation in cardiomyocytes cell death by targeting Bcl-2.

Authors:  Chuanyu Wei; Li Li; Sudhiranjan Gupta
Journal:  Mol Cell Biochem       Date:  2013-11-01       Impact factor: 3.396

3.  Adipocyte-specific loss of PPARγ attenuates cardiac hypertrophy.

Authors:  Xi Fang; Matthew J Stroud; Kunfu Ouyang; Li Fang; Jianlin Zhang; Nancy D Dalton; Yusu Gu; Tongbin Wu; Kirk L Peterson; Hsien-Da Huang; Ju Chen; Nanping Wang
Journal:  JCI Insight       Date:  2016-10-06

4.  Angiotensin receptor type 1 single nucleotide polymorphism 1166A/C is associated with malignant arrhythmias and altered circulating miR-155 levels in patients with chronic heart failure.

Authors:  Raul R Blanco; Harland Austin; Richard N Vest; Ravinder Valadri; Wei Li; Bernard Lassegue; Qing Song; Barry London; Samuel C Dudley; Heather L Bloom; Charles D Searles; A Maziar Zafari
Journal:  J Card Fail       Date:  2012-08-09       Impact factor: 5.712

Review 5.  Thyroid hormones and cardiac remodeling.

Authors:  Dennis V Cokkinos; Stavros Chryssanthopoulos
Journal:  Heart Fail Rev       Date:  2016-07       Impact factor: 4.214

Review 6.  Molecular switches under TGFβ signalling during progression from cardiac hypertrophy to heart failure.

Authors:  J Heger; R Schulz; G Euler
Journal:  Br J Pharmacol       Date:  2015-11-16       Impact factor: 8.739

Review 7.  Left ventricular assist device-induced reverse remodeling: it's not just about myocardial recovery.

Authors:  Karolina K Marinescu; Nir Uriel; Douglas L Mann; Daniel Burkhoff
Journal:  Expert Rev Med Devices       Date:  2016-12-22       Impact factor: 3.166

8.  Differential expression of vascular smooth muscle-modulating microRNAs in human peripheral blood mononuclear cells: novel targets in essential hypertension.

Authors:  J E Kontaraki; M E Marketou; E A Zacharis; F I Parthenakis; P E Vardas
Journal:  J Hum Hypertens       Date:  2013-11-28       Impact factor: 3.012

Review 9.  The role of redox signaling in epigenetics and cardiovascular disease.

Authors:  Gene H Kim; John J Ryan; Stephen L Archer
Journal:  Antioxid Redox Signal       Date:  2013-03-12       Impact factor: 8.401

10.  miRNA expression in pediatric failing human heart.

Authors:  Brian L Stauffer; Gloria Russell; Karin Nunley; Shelley D Miyamoto; Carmen C Sucharov
Journal:  J Mol Cell Cardiol       Date:  2013-01-17       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.